Lyonisation, or X-chromosome inactivation, is the physiological process ensuring dosage compensation by transcriptionally silencing one of the two X chromosome copies in female mammals.
Proposed by British geneticist Mary Lyon in 1961, this mechanism ensures that females (XX) and males (XY) produce equal amounts of X-linked gene products.
The inactivated X chromosome condenses into a transcriptionally inert structure called the Barr body, typically situated at the periphery of the interphase nucleus.
Core Postulates Of The Lyon Hypothesis
Random Inactivation: In normal female somatic cells, the selection of the maternal or paternal X chromosome for inactivation is entirely random.
Fixed And Clonal Nature: Once an X chromosome is inactivated in an embryonic cell, it remains inactive in all descendant cells, making females functional mosaics for X-linked genes.
Completeness: Inactivation does not suppress the entire chromosome; approximately 15 to 20% of genes “escape” inactivation. These are primarily located in the pseudoautosomal regions (PAR1 and PAR2), which share functioning homologues on the Y chromosome.
Embryology And Timeline
Pre-implantation Stage: Both X chromosomes remain transcriptionally active in the early zygote.
Imprinted Inactivation: In extraembryonic tissues destined to form the placenta, the paternally derived X chromosome undergoes preferential, non-random inactivation.
Random Inactivation: In the inner cell mass (embryo proper), the initial imprinted inactivation is reversed, and random inactivation occurs around the blastocyst implantation stage.
Germline Reversal: In primordial germ cells, the inactive X chromosome reactivates prior to meiosis, ensuring every ovum receives a fully active X chromosome.
Molecular Mechanisms Of X-Inactivation
The process is governed by the X-Inactivation Center located on the q arm of the X chromosome (Xq13.2).
Mechanism Component
Function And Action
XIST
Master regulator gene within the X-Inactivation Center encoding a long non-coding RNA. It is upregulated on the inactive X chromosome and physically coats it in cis.
Tsix
An overlapping gene transcribed in the antisense direction, acting as a repressor of XIST. High expression on the active X chromosome prevents XIST accumulation.
DNA Methylation
Cytosine residues at CpG islands in promoter regions are heavily methylated to ensure transcriptional silencing.
Histone Modifications
Histone deacetylation (H3 and H4) and specific methylation (H3K27me3) condense chromatin into heterochromatin.
Histone Variants
Incorporation of the macroH2A histone variant enriches the Barr body and maintains structural compaction.
Replication Timing
The inactive X chromosome replicates late in the S phase of the cell cycle.
Skewed X-Inactivation
Normal X-inactivation yields a roughly 50:50 ratio of active maternal to paternal X chromosomes.
Definition: Skewed X-inactivation is a significant deviation, defined by an activation ratio greater than 80:20 or 90:10 favoring one X chromosome.
Primary Skewing: Arises from stochastic chance in early embryogenesis or due to a mutation in the X-Inactivation Center.
Secondary Skewing: A selection-driven, post-inactivation event where cells harboring a lethal or highly deleterious mutation on the active X chromosome undergo apoptosis, allowing cells with the healthy active X to outgrow them.
Clinical Implications In Pediatrics
Disease Category
Pathophysiological Implications
Clinical Examples
X-Linked Recessive
Adverse skewing can lead to a “manifesting carrier” state in females. Alternatively, secondary skewing provides a survival advantage, heavily favoring the normal X chromosome.
Manifesting females with Duchenne Muscular Dystrophy (proximal weakness, cardiomyopathy) or Hemophilia A/B. Female carriers of X-Linked Severe Combined Immunodeficiency demonstrate 100% skewing favoring the normal X in T-cells.
X-Linked Dominant
Functional mosaicism determines disease severity and physical patterns. Cellular interference between active and inactive mutant cell populations can sometimes make females more severely affected than males.
Rett syndrome severity (MECP2 mutation) depends on brain inactivation patterns. Incontinentia Pigmenti skin lesions follow Lines of Blaschko, visualizing clonal expansion. Craniofrontonasal dysplasia (EFNB1) is more severe in females.
Structural Abnormalities
Secondary skewing protects the cell by selectively inactivating specific chromosomes.
In X-autosome translocations, the normal X is inactivated to prevent lethal monosomy of the autosome. In isochromosomes (e.g., isochromosome Xq), the abnormal X is almost exclusively inactivated.
Aneuploidies
Phenotypes arise from the abnormal dosage of the 15-20% of X-linked genes that normally escape inactivation.
Turner Syndrome (45,X) exhibits haploinsufficiency of escape genes like SHOX. Klinefelter Syndrome (47,XXY) undergoes X-inactivation, but overexpression of escape genes leads to tall stature and hypogonadism.
Diagnostic Evaluation
HUMARA Assay: The clinical gold standard for assessing X-inactivation skewing utilizes the Human Androgen Receptor gene.
Mechanism: It relies on a highly polymorphic CAG repeat in the first exon of the Androgen Receptor gene on the X chromosome.
Procedure: Methylation-sensitive restriction enzymes (such as HpaII) are applied. The hypermethylated inactive X resists cleavage, while the unmethylated active X is cleaved. Polymerase chain reaction amplification subsequently quantifies the ratio of maternal to paternal active alleles.
